India hematology transplant cost guide

Bone marrow transplant cost in India by transplant type and donor pathway

Bone marrow transplant, more precisely hematopoietic stem cell transplant, is a multi-stage treatment rather than a single infusion. Eligibility, disease status, autologous or allogeneic source, HLA match, donor search and collection, conditioning intensity, protected admission, engraftment, infection, graft-versus-host disease, blood products and prolonged follow-up determine the complete cost.

How much does bone marrow transplant cost in India?

For 2026 planning, an autologous transplant may cost about INR 12,00,000-20,00,000 (USD 12,500-20,800), while matched-related allogeneic care may cost INR 20,00,000-35,00,000 (USD 20,800-36,400). Haploidentical, unrelated-donor, cord, severe infection, ICU, graft failure, or GVHD pathways can reach INR 30,00,000-55,00,000+ (USD 31,200-57,200+).

USD values are rounded at about INR 96.22 per USD using the RBI display on July 15, 2026. Cell procurement, imported medicines, blood products, complications, and exchange movement can materially alter the paid amount.

Review cost scenarios Upload reports

Let Us Help You

Share the basics and the Virello team will guide you toward the next step.

Prefer email? Write to support@virellohealth.com.

Patient Name

Country

Phone Number

Describe The Current Medical Problem

Reviewed 2026-07-18

Clinical review: Virello Health Clinical Review Team · Editorial review: Virello Health Medical Travel Editorial Team

Billing context: INR and USD

Not an organ transplant

Blood-forming stem cells may come from peripheral blood, bone marrow, or cord blood; the patient receives them by infusion after conditioning.

Typical timeline

Evaluation, collection, conditioning, protected admission, engraftment, and close local monitoring can span weeks to months.

Main cost uncertainty

Infection, blood-product use, GVHD, delayed engraftment, donor procurement, ICU, and readmission can exceed routine allowances.

Long immune recovery

Counts can recover before immune function; allogeneic recovery and vaccination planning can continue for one to two years.

Cost at a glance

Planning scenarios for bone marrow transplant in India

The scenarios separate routine and complex pathways. They are not fixed packages and should be replaced by a report-led hospital estimate before travel.

Estimated bone marrow transplant cost scenarios in India
Scenario	INR	USD	Patient and treatment context	Planning scope
Autologous transplant	INR 12,00,000-20,00,000	USD 12,500-20,800	Selected lymphoma, myeloma, or other indication using the patient’s collected cells after high-dose conditioning.	Mobilization, apheresis, storage, conditioning, infusion, protected admission, routine blood support, and stated follow-up limits must be itemized.
Matched-related allogeneic transplant	INR 20,00,000-35,00,000	USD 20,800-36,400	Eligible patient with a suitable related HLA-matched donor and a defined conditioning and GVHD-prevention pathway.	Recipient and donor workup, collection, conditioning, isolation, immunosuppression, engraftment monitoring, and early outpatient care.
Haploidentical, unrelated, cord, or complicated pathway	INR 30,00,000-55,00,000+	USD 31,200-57,200+	Alternative donor source, registry procurement, intensive conditioning, slow engraftment, major infection, GVHD, graft failure, or ICU need.	Donor search, product logistics, high-cost antimicrobials, ICU, readmission, cellular rescue, and prolonged local stay may sit outside a base quote.

Usually included

Check the clinical package scope

Recipient eligibility workup

Disease status, marrow or imaging, organ function, infection screening, dental review, fertility discussion, and psychosocial assessment.

Ask which tests are included or repeated.

Cell pathway

Mobilization, apheresis or marrow collection, CD34 testing, processing, cryopreservation, transport, and infusion as applicable.

Unrelated registry and courier charges need separate confirmation.

Conditioning and protected admission

Named chemotherapy or radiation conditioning, room, hematology care, nursing, routine monitoring, and infection precautions within day limits.

Record isolation-day assumptions.

Routine supportive care

Standard transfusion, antimicrobial prophylaxis, growth factor, nutrition, mucositis, and laboratory support as defined.

High-cost or prolonged products may be excluded.

Early post-transplant review

Engraftment checks, chimerism when relevant, immunosuppression plan, warning signs, medicines, and local handover.

Ask how many outpatient days are bundled.

Confirm separately

Charges that may sit outside the range

Donor search and procurement

Registry search, confirmatory HLA, unrelated or cord product, collection-center fee, courier, and donor travel.

Obtain a written source-specific budget.

Bridging or salvage therapy

Chemotherapy, targeted therapy, immunotherapy, radiation, or another procedure needed to control disease before transplant.

This is usually a separate phase.

Major infection or GVHD care

Advanced microbiology, costly antifungals or antivirals, ICU, ventilation, endoscopy, biopsy, and intensified immunosuppression.

Request daily overage and medicine rules.

Graft failure or cellular rescue

Repeat collection, stem-cell boost, second transplant, donor lymphocyte infusion, or prolonged growth support.

Not part of routine package assumptions.

Long-term recovery

Accommodation, outpatient transfusions, readmission, vaccinations, endocrine or fertility care, rehabilitation, and home-country tests.

Plan beyond day 100.

Candidate context

Who may be considered and what else may be discussed

Suitability depends on diagnosis, remission or response, prior therapy, available cell source, HLA matching, age and physiologic reserve, infection status, heart-lung-kidney-liver function, fertility goals, psychosocial support, and ability to remain near the transplant center. The transplant team must compare BMT with non-transplant treatment and explain expected benefit for the specific disease.

Information that shapes suitability

Disease and timing

Current marrow, flow, cytogenetic, molecular, imaging, and treatment response determine whether transplant is indicated now.

Cell-source feasibility

Autologous collection potential or related, haploidentical, unrelated, or cord HLA options shape the plan.

Organ and infection fitness

Cardiac, respiratory, kidney, liver, dental, viral, bacterial, and fungal risk are assessed before conditioning.

Caregiver and follow-up readiness

A reliable caregiver, clean nearby accommodation, medication access, urgent transport, and home hematology are essential.

Alternatives or sequencing questions

Continued systemic therapy

Chemotherapy, targeted, immune, or disease-modifying treatment may be preferred when transplant benefit is limited or disease control is inadequate.

Autologous versus allogeneic strategy

The patient’s own cells avoid GVHD, while donor cells provide a graft-versus-disease effect for selected conditions but add immune risk.

Different donor source

Matched sibling, haploidentical relative, matched unrelated, and cord pathways differ in availability, procurement, engraftment, GVHD, and cost.

CAR-T or clinical study

Selected relapsed or refractory blood cancers may have a cellular-therapy or research option requiring separate eligibility review.

Procedure variations

Why the named procedure does not have one price

Technique, device, medicine, treatment extent, and prior care can change both the clinical plan and the estimate.

Autologous HSCT

Patient cells are mobilized, collected, stored, and returned after high-dose treatment.

Collection failure or extra apheresis adds cost.

Matched-related allogeneic HSCT

A closely HLA-matched relative provides cells and the recipient receives GVHD prevention.

Donor health and independent consent remain central.

Haploidentical transplant

A half-matched family donor can expand access with a specific immune-management protocol.

Compare conditioning, GVHD prophylaxis, and infection support.

Unrelated or cord transplant

Registry or bank search, confirmatory typing, procurement, and international logistics may be required.

Product availability and delivery timing affect treatment.

City comparison

Cost and capability by city in India

Only cities with evidence for the procedure should appear here. A city range does not prove that every hospital in that city can manage the same case complexity.

Estimated bone marrow transplant costs and planning context by city in India
City	Local range	USD range	Capability context	Stay planning
Mumbai	INR 14,00,000-55,00,000+	USD 14,500-57,200+	Selected centers provide adult and pediatric hematology, unrelated donor access, intensive infection support, and cellular therapy.	Compare public or charitable eligibility with private timelines.
Delhi NCR and Gurugram	INR 14,00,000-52,00,000+	USD 14,500-54,000+	Multiple tertiary private and institutional transplant units support complex donor pathways and critical care.	Budget prolonged lodging near the chosen campus.
Bengaluru	INR 13,00,000-48,00,000+	USD 13,500-49,900+	Established hematology programs offer autologous and allogeneic care with laboratory and ICU support.	Confirm unrelated registry and pediatric capability case by case.
Chennai	INR 13,00,000-47,00,000+	USD 13,500-48,800+	Selected programs manage adult, pediatric, donor, infection, and long-stay transplant pathways.	Check accommodation and outpatient transfusion access.
Hyderabad	INR 13,00,000-46,00,000+	USD 13,500-47,800+	Tertiary hospitals offer transplant hematology, protected rooms, blood bank, and critical care.	Verify the exact disease and donor-source experience.
Kolkata	INR 12,50,000-43,00,000+	USD 13,000-44,700+	Regional referral centers provide selected adult and pediatric HSCT pathways.	Review infection and readmission infrastructure.
Ahmedabad	INR 12,50,000-42,00,000+	USD 13,000-43,700+	Selected cancer and multispecialty centers provide hematology transplant care.	Confirm donor registry logistics and ICU backup.
Pune	INR 13,00,000-43,00,000+	USD 13,500-44,700+	Some tertiary units support standard autologous and allogeneic pathways.	Ask where complex infection or cellular rescue is managed.
Kochi or Thiruvananthapuram	INR 12,50,000-42,00,000+	USD 13,000-43,700+	Selected Kerala centers offer transplant hematology and prolonged follow-up.	Regional proximity can reduce post-discharge burden.
Indore, Nagpur or other value city	INR 12,00,000-35,00,000+	USD 12,500-36,400+	Only verified units with protected rooms, hematopathology, apheresis, blood bank, microbiology, ICU, and experienced teams should be considered.	Alternative-donor or unstable cases may require a larger referral center.

Estimate variables

What can change the final hospital cost

Transplant and donor type

Autologous, sibling, haploidentical, unrelated, and cord pathways require different collection, products, and immune management.

Name the pathway in every quote.

Disease status and bridging

Active or resistant disease may require more treatment before conditioning and can increase relapse or complication risk.

Price pre-transplant therapy separately.

Conditioning intensity

Myeloablative or reduced-intensity regimens differ by drug, radiation, organ risk, and supportive care.

Ask for regimen names.

Engraftment and blood support

Collection yield, count recovery, transfusions, growth factors, and chimerism testing affect admission length.

Define included units and days.

Infection and GVHD

Prolonged neutropenia, resistant infection, CMV or fungal disease, and acute or chronic GVHD can dominate cost.

High-cost medicines are often actuals.

Readmission and immune recovery

Fever, dehydration, organ toxicity, graft failure, immunosuppression, and vaccination continue after discharge.

Model at least the first 100 days.

Medical cost breakdown

Before admission, in hospital, and after discharge

Diagnostics and preparation

Disease reassessment

Marrow, flow, cytogenetics, molecular residual disease, pathology, PET-CT or other imaging as appropriate.

Current response determines timing.

HLA and donor workup

Recipient and donor typing, confirmatory tests, compatibility, infectious screening, and donor medical assessment.

Registry search is additional.

Organ and infection fitness

Blood, kidney, liver, cardiac, lung, dental, viral, bacterial, fungal, and reproductive evaluation.

Abnormalities may delay conditioning.

Collection planning

Venous access, mobilization plan, CD34 monitoring, apheresis, marrow harvest, processing, and storage.

Extra collection days need pricing.

Admission and treatment

Conditioning treatment

Named chemotherapy or radiation, central line, hydration, monitoring, and organ-protection support.

Regimen determines toxicity.

Stem-cell product and infusion

Collection or procurement, processing, storage, transport, verification, thawing, and infusion.

Keep product and donor records.

Protected inpatient care

Hematology, room, nursing, daily laboratory, transfusion, nutrition, antimicrobials, and engraftment monitoring.

Ask included day and product limits.

Complication escalation

ICU, bronchoscopy, endoscopy, biopsy, dialysis, ventilation, resistant-infection drugs, or GVHD treatment.

Usually billed beyond base package.

Recovery and follow-up

Frequent outpatient monitoring

Counts, organ tests, drug levels, chimerism, infection surveillance, line care, and transfusion.

Remain close to the center as directed.

Immunosuppression and prophylaxis

GVHD prevention, antiviral, antifungal, antibacterial, and other medicines may continue for months.

Confirm home-country availability.

Nutrition and rehabilitation

Mucositis recovery, safe food, weight, strength, fatigue, fertility, endocrine, and psychosocial support.

Immune precautions are individualized.

Revaccination and late effects

Vaccines, organ, bone, endocrine, fertility, secondary-cancer, relapse, and chronic-GVHD surveillance.

Long-term hematology follow-up is mandatory.

Complete journey budget

Plan beyond the hospital invoice

Patient and attendant costs should be modeled separately from the medical estimate, with flexible dates and a contingency reserve.

Patient, donor, and caregiver travel

Flexible tickets, donor collection travel, caregiver changes, mobility support, and delayed return.

Donor and recipient may have different dates.

Visa and medical records

Medical visa, attendant or donor documentation, translations, tissue or cell logistics, and courier costs.

Confirm current rules officially.

Protected local accommodation

Clean lodging near the transplant center with safe food, transport, hygiene, and emergency access.

Post-discharge stay can be prolonged.

Medicines and outpatient care

Drug supply, laboratory monitoring, transfusions, line care, clinic visits, and home-country handover.

Price the first 100 days separately.

Complication reserve

Readmission, high-cost antimicrobials, GVHD, ICU, extra blood products, delayed engraftment, or changed flights.

Keep substantial funds beyond the base quote.

Country access

Rules and practical requirements to verify

Visa, donor, fertility, medicine, licensing, and treatment-access requirements can change. Confirm current rules with the relevant authority and treating hospital.

Use official medical visa guidance

Check current patient, attendant, donor, stay, entry, and document requirements through the Government of India portal.

Verify donor consent and collection rules

A donor requires independent medical and psychosocial evaluation, informed consent, privacy, and a plan for collection complications and follow-up.

Clarify cell import or registry logistics

For unrelated or cord products, confirm registry, collection center, courier, customs, chain of identity, viability, cancellation, and refund terms.

Treat fever as urgent

During neutropenia or immune suppression, fever, breathing difficulty, confusion, bleeding, severe diarrhea, rash, jaundice, or reduced urine needs immediate transplant-team contact.

Hospital selection

Compare capability before package price

Disease and donor-pathway experience

Ask about the exact diagnosis, autologous, sibling, haploidentical, unrelated, cord, pediatric, and salvage experience relevant to the case.

Avoid generic transplant counts.

Cell laboratory and apheresis

Verify collection, CD34 testing, processing, cryopreservation, quality, identity, transport, backup storage, and release procedures.

These are core transplant systems.

Protected unit and infection program

Check room engineering, microbiology, antimicrobial stewardship, isolation practice, ICU, and outbreak response.

Ask how infections are billed.

Blood bank and critical backup

Confirm irradiated or specialized products, 24-hour transfusion, bronchoscopy, dialysis, ventilation, and multispecialty support.

Complex toxicity needs immediate access.

GVHD and readmission pathway

Review prophylaxis, drug-level testing, skin-gut-liver evaluation, outpatient triage, day care, and emergency admission.

Allogeneic care continues after discharge.

Itemized estimate

Require donor search, collection, conditioning, room days, products, medicines, tests, ICU, readmission, follow-up, and cancellation terms.

One package total is insufficient.

Treating team

Specialists and support that may matter

Transplant hematologist

Confirms indication, disease control, donor strategy, conditioning, immune plan, and long-term follow-up.

Cell-therapy and laboratory team

Manages HLA, apheresis, collection, processing, storage, identity, product release, and infusion.

Infectious-disease and microbiology team

Guides prevention, rapid diagnosis, resistant infection, antiviral and antifungal care.

Critical-care and organ specialists

Support respiratory, kidney, liver, cardiac, neurologic, and ICU complications.

Nutrition, rehabilitation, and psychosocial team

Supports mucositis, weight, strength, caregiver burden, fertility, mental health, and home transition.

Hospital comparison guides

Compare hospitals around this exact treatment decision

Use these report-led guides to compare programme capability, clinical support, city fit, verification questions, recovery planning, and continuity after returning home.

Compare bone marrow transplant hospitals

Review transplant type, donor testing, authorization, infection control, blood-bank support, and long-term follow-up.

Treatment timeline

From report review to return-home follow-up

1. Disease and eligibility review

Current response, prior therapy, organ reserve, infection, and transplant alternatives are assessed.

2. Cell-source plan

Autologous collection or related, haploidentical, unrelated, or cord options are tested and compared.

3. Itemized pathway and logistics

Conditioning, collection, admission, medicines, donor dates, visa, lodging, and complication reserves are planned.

4. Mobilization or donor collection

Cells are collected, tested, processed, stored, or transported under documented controls.

5. Conditioning and day zero

The patient receives preparative treatment followed by stem-cell infusion.

6. Engraftment and protected recovery

Counts, infection, bleeding, organ function, nutrition, and GVHD are monitored through discharge.

7. Day-100 and long-term care

Immune recovery, chimerism, relapse, GVHD, medicines, revaccination, and late effects continue with local hematology.

Risks and edge cases

Events that can change the plan, stay, or cost

Collection failure or donor change

Poor mobilization, donor exclusion, product issue, or disease progression can require another collection or source.

Clarify sunk and refundable costs.

Severe infection

Bacterial, viral, fungal, or resistant infection can cause prolonged admission, ICU, and high-cost treatment.

Fever requires immediate response.

GVHD

Donor immune cells can affect skin, gut, liver, lung, or other organs acutely or chronically.

This risk applies to allogeneic pathways.

Graft failure or delayed engraftment

Counts may not recover as expected, adding transfusions, infection risk, growth support, or another cell procedure.

Ask about rescue capability.

Organ toxicity and ICU

Conditioning and immune complications can affect heart, lung, kidney, liver, brain, or clotting.

Base packages rarely cover full escalation.

Relapse and late effects

Disease can return and survivors may face infertility, endocrine, bone, organ, chronic GVHD, or second-cancer risks.

Transplant does not guarantee cure.

Destination comparison

Compare India, Turkey, and Thailand for this procedure

The most suitable destination depends on the individual case, required team, treatment availability, travel route, legal eligibility, budget, and continuity after returning home.

Procedure planning comparison across India, Turkey, and Thailand
Decision factor	India	Turkey	Thailand	How to use this
Transplant range	Autologous planning can begin near USD 12,500; complex donor pathways may exceed USD 57,000.	Private programs may quote in EUR or USD with donor procurement separate.	International centers may bundle private admission differently in THB or USD.	Compare identical donor source, conditioning, room days, products, and follow-up.
Donor and laboratory access	Selected metros provide HLA, apheresis, cell processing, registries, haploidentical and cellular-therapy pathways.	Advanced donor care clusters in specialist programs.	Major Bangkok programs offer selected complex HSCT services.	Verify the exact disease and donor-source experience.
Infection and readmission	Capability varies widely; select protected units with strong microbiology, blood bank, ICU, and readmission systems.	Confirm isolation and high-cost antimicrobial inclusions.	Check outpatient proximity and complication billing.	Safety systems matter more than a low base package.
Long local stay	Multiple cost tiers can reduce accommodation, but patients must remain near the transplant unit as directed.	Flight proximity may suit nearby regions.	International coordination may ease long stays at a higher non-medical cost.	Price caregiver and day-100 logistics.

Decision guidance

When India may fit and when to keep comparing

India may fit when

The transplant indication is independently confirmed, disease is controlled enough, a suitable cell source and experienced unit are available, and long follow-up is funded.

A major referral center may fit when

The patient needs alternative donor, pediatric, rare-disease, major infection, organ support, cellular rescue, or previous-transplant expertise.

A value city may fit when

The pathway is standard and the unit has verified cell laboratory, protected rooms, blood bank, microbiology, ICU, and experienced transplant follow-up.

Local care may be safer when

The disease is rapidly unstable, infection is uncontrolled, travel is unsafe, or prolonged home-country transplant follow-up cannot be secured.

Reports for review

Prepare a case file before requesting estimates

Send the complete diagnostic and treatment chronology, marrow and pathology, flow, cytogenetic and molecular reports, current response imaging, every prior drug and dose, HLA work already done, donor relationships and health information, blood and organ trends, infections, transfusions, fertility priorities, and the proposed transplant recommendation.

Upload medical reports

Disease and transplant evidence

These establish indication, timing, and donor strategy.

Marrow and pathology

Include morphology, flow, cytogenetics, molecular results, minimal residual disease, dates, slides, and blocks.

Treatment and response chronology

List every regimen, dose, cycle, complication, response, relapse, radiation, and cellular treatment.

HLA and donor records

Provide recipient and donor typing, relationships, compatibility, registry searches, collection, and infectious screening.

Current disease imaging

Share PET-CT, CT, MRI, or other studies used for response and transplant timing.

Fitness and continuity

These details determine conditioning and recovery safety.

Blood and organ trends

Include CBC, kidney, liver, electrolytes, cardiac and lung testing, coagulation, and transfusion history.

Infection and immune history

Send viral serology, cultures, prior resistant infection, fungal disease, vaccinations, and current antimicrobials.

Medical and fertility history

Describe comorbidities, allergies, prior transplant, reproductive goals, nutrition, mobility, and psychosocial needs.

Caregiver and home plan

Identify caregiver, local hematologist, emergency hospital, medicine supply, accommodation, and travel constraints.

Common questions

Questions about cost, travel, and follow-up

Are BMT and stem cell transplant the same?

BMT is commonly used for hematopoietic stem cell transplant. The cells may come from peripheral blood, bone marrow, or cord blood, and may be the patient’s own or a donor’s.

Why does allogeneic transplant cost more?

It adds donor HLA and fitness work, collection or procurement, GVHD prevention, immunosuppression, chimerism, longer immune recovery, and greater infection and readmission risk.

Does the package include donor search?

Not automatically. Related testing, unrelated registry search, confirmatory typing, collection-center fees, cord product, courier, and donor travel should be itemized.

How long must an international patient remain in India?

The transplant center decides from engraftment, infection, medicines, GVHD, transfusion needs, caregiver readiness, and home support. Many patients need weeks of nearby monitoring after discharge.

What is graft-versus-host disease?

In an allogeneic transplant, donor immune cells can attack the recipient’s tissues. It may affect skin, gut, liver, lung, and other organs and can require prolonged treatment.

Can a Tier 2 city provide BMT?

Only a verified transplant unit with disease-specific experience, HLA and cell systems, protected rooms, blood bank, microbiology, ICU, and rapid readmission should be considered.

What commonly raises the final bill?

Donor procurement, extra collection, delayed engraftment, transfusions, resistant infection, high-cost antifungal or antiviral medicine, GVHD, ICU, and readmission are common drivers.

Can the patient fly immediately after count recovery?

No fixed count alone proves travel readiness. The team considers infection, hydration, medicines, line care, GVHD, transfusions, emergency access, and flight conditions.

Does transplant guarantee that cancer will not return?

No. Transplant may improve disease control or offer curative potential for selected conditions, but relapse and serious short- and long-term complications remain possible.

Does Virello decide transplant eligibility?

No. A transplant hematology team determines eligibility and donor strategy. Virello can organize records and compare written pathway assumptions without guaranteeing cost or outcome.

Review and sources

How this guide was prepared

Virello compared current Indian institutional charges and market ranges with recognized transplant guidance. Scenarios are separated by autologous, matched-related, and alternative-donor or complicated pathways because donor procurement, isolation, engraftment, infection, GVHD, blood support, and readmission make a single BMT average misleading.

This guide is educational and does not determine transplant eligibility, donor suitability, conditioning, or outcome. Fever, bleeding, breathlessness, confusion, severe diarrhea, rash, jaundice, reduced urine, or rapid deterioration during transplant care requires immediate specialist assessment.

Related planning